ARAY חוב כולל להון Accuray Inc.

Accuray Incorporated (ARAY) experienced management is successfully scaling the brand's international presence, as reflected in the price chart where the debt-to-equity ratio stands at 4.38. The company generates revenue through the sale of robotic systems and the maintenance of tumor radiation equipment. However, the business faces intense competition for government procurement and the risk of falling behind in the field of digital therapy planning.

Investors must assess the balance sheet resilience of Accuray Incorporated (ARAY) against potential interest rate risks. This ratio compares total liabilities to net assets to determine the degree of financial leverage. The trend of the company's debt-to-equity ratio demonstrates the business's reliance on borrowed funds. Excessive debt load could limit the production development of CyberKnife robotic systems. The stability of this metric confirms the company's ability to scale equipment sales for oncology centers.